Capella-Peris Carlos, Emile-Backer Magalie, Shelton Monique O, Chrismer Irene C, Cosgrove Mary M, Bendixen Roxanna M, Meilleur Katherine G
Neuromuscular Symptoms Unit, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA.
Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, USA.
J Adv Nurs. 2021 Mar;77(3):1591-1608. doi: 10.1111/jan.14687. Epub 2020 Dec 3.
To develop a novel proxy-reported scale of motor function in infants and young children with early-onset neuromuscular disorders (NMD), entitled the Proxy Motor Outcome Measure (PMOM).
A mixed method design was employed, applying both qualitative and quantitative research.
A framework technique using sensitivity analyses guided the development of the most appropriate and relevant subset of items, modelled after 30 neuromuscular disease instruments/scales. The PMOM was designed based on semi-structured interviews with 16 proxies; a focus group of 11 experts in neuromuscular diseases and scale development, 10 of whom also gave quantitative data using a two-round Delphi method survey; and cognitive interviews with five proxies. These processes were conducted between January 2014-March 2019.
Nine themes and 32 subthemes were derived from the semi-structured interviews. Five domains and three subdomains of potential items were identified by the focus group. An initial version of the PMOM scale was created with 121 items. Using the two-round Delphi method, 43 items met agreement on pre-defined requirements. The second version of the PMOM scale included these 43 and two additional items based on expert feedback. Proxies gave 114 suggestions on cognitive interviews, 99 of which were successfully addressed by the research team. The final version of the PMOM scale included 43 items.
We developed a preliminary proxy-reported instrument, the PMOM, to evaluate motor function in infants and young children with early-onset NMD.
Proxies hold a wealth of knowledge on their child's motor function during early development, which may complement clinic-based motor function testing. However, there is no validated measure of motor function that incorporates the observation of proxies of infants and young children with NMD. Future work will be focused on assessing the reliability, validity and responsiveness of the PMOM scale and implementing this tool in clinical studies.
开发一种针对早发性神经肌肉疾病(NMD)婴幼儿的新颖的代理报告运动功能量表,即代理运动结果测量量表(PMOM)。
采用混合方法设计,运用定性和定量研究。
采用框架技术并结合敏感性分析,以30种神经肌肉疾病工具/量表为蓝本,指导开发最合适、最相关的项目子集。PMOM基于对16名代理人的半结构化访谈设计而成;一个由11名神经肌肉疾病及量表开发专家组成的焦点小组,其中10人还通过两轮德尔菲法调查提供了定量数据;以及对5名代理人的认知访谈。这些过程于2014年1月至2019年3月期间进行。
半结构化访谈得出9个主题和32个子主题。焦点小组确定了潜在项目的5个领域和3个子领域。创建了一个包含121个项目的PMOM量表初始版本。通过两轮德尔菲法,43个项目符合预定义要求。PMOM量表的第二版包括这43个项目以及基于专家反馈增加的另外两个项目。代理人在认知访谈中提出了114条建议,其中99条已由研究团队成功解决。PMOM量表的最终版本包括43个项目。
我们开发了一种初步的代理报告工具PMOM来评估早发性NMD婴幼儿的运动功能。
代理人在其孩子早期发育过程中对运动功能掌握着丰富知识,这可能补充基于临床的运动功能测试。然而,目前尚无经过验证的运动功能测量方法能纳入对NMD婴幼儿代理人的观察。未来工作将集中于评估PMOM量表的信度、效度和反应度,并在临床研究中应用该工具。